Today’s medical knowledge, technology and data science offer an enormous promise: the right treatment for the right patient at the right time. If we work together, we can make this a reality for patients worldwide. Personalized Healthcare gets down to the molecular roots of disease. It is more important to know what sort of person has a disease than what sort of disease a person has. Personalized Healthcare aims to provide targeted therapies tailored to the inherited or acquired risk factors displayed by different subgroups of patients. The foundations for this new, highly sensitive approach are the findings produced by modern research; research that is able to trace the origins of a disease back to its molecular causes and thus supply spectacular insights into the complexity of the factors that lead to disease.
Personalized healthcare (PHC) is not only about treating and preventing disease for individual patients. It is also about rethinking the healthcare system for future generations. In India, Foundation Medicine’s high-quality portfolio of comprehensive genomic profiling services helps healthcare professionals to optimize and personalize treatment strategies for patients in diverse clinical situations, to drive better treatment outcomes.
For many years, personalized healthcare meant testing for a disease-related biomarker and providing a targeted treatment. Today, we’re expanding and connecting this personalized approach across the patient care continuum to deliver evidence-based, technology-enabled healthcare solutions tailored to the individual.
We are:
Increasing understanding of tumors and providing insights on clinical trials to consider, to enable smarter, more efficient research and development.
Improving patient care by providing genomic insights with associated targeted therapies, immunotherapies and relevant clinical trials.
As our understanding of cancer evolves, so do our tests. Our continuously growing genomic database currently includes over 200,000 genomic profiles in over 150 common and rare tumor subtypes. Advanced bioinformatics interpret the data, including rare and complex alterations, to generate powerful insights. Our tests are constantly evolving to capture the most clinically relevant genomic alterations so you stay up-to-date and the latest treatment options can be considered.
Our pioneering, FDA-validated, tissue-based, comprehensive genomic profiling service for all solid tumors.
FDA-approved liquid biopsy comprehensive genomic profiling service offers a minimally-invasive option, alternative or complementary to FoundationOne CDx, for all patients with solid tumors.
Comprehensive genomic profiling service for hematological malignancies and sarcomas.
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin. This website is neither intended nor designed to record or report adverse event information. If you have a suspected side effect or problem to report regarding one of our products, visit us at